| Year |
Citation |
Score |
| 2020 |
Lim CJ, Nguyen PHD, Wasser M, Kumar P, Lee YH, Nasir NJM, Chua C, Lai L, Hazirah SN, Loh JJH, Khor LY, Yeong J, Lim TKH, Low AWX, Albani S, ... Chong TW, et al. Immunological Hallmarks for Clinical Response to BCG in Bladder Cancer. Frontiers in Immunology. 11: 615091. PMID 33584702 DOI: 10.3389/fimmu.2020.615091 |
0.314 |
|
| 2012 |
Yuen JS, Sim MY, Sim HG, Chong TW, Lau WK, Cheng CW, Ong RW, Huynh H. Combination of the ERK inhibitor AZD6244 and low-dose sorafenib in a xenograft model of human renal cell carcinoma. International Journal of Oncology. 41: 712-20. PMID 22641227 DOI: 10.3892/ijo.2012.1494 |
0.354 |
|
| 2004 |
Silk JD, Hermans IF, Gileadi U, Chong TW, Shepherd D, Salio M, Mathew B, Schmidt RR, Lunt SJ, Williams KJ, Stratford IJ, Harris AL, Cerundolo V. Utilizing the adjuvant properties of CD1d-dependent NK T cells in T cell-mediated immunotherapy. The Journal of Clinical Investigation. 114: 1800-11. PMID 15599405 DOI: 10.1172/Jci200422046 |
0.498 |
|
| 2003 |
Hermans IF, Chong TW, Palmowski MJ, Harris AL, Cerundolo V. Synergistic effect of metronomic dosing of cyclophosphamide combined with specific antitumor immunotherapy in a murine melanoma model. Cancer Research. 63: 8408-13. PMID 14679003 |
0.494 |
|
| 2002 |
Chong TW, Horwitz LD, Moore JW, Sowter HM, Harris AL. A mycobacterial iron chelator, desferri-exochelin, induces hypoxia-inducible factors 1 and 2, NIP3, and vascular endothelial growth factor in cancer cell lines. Cancer Research. 62: 6924-7. PMID 12460908 |
0.412 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2008 |
Loong SL, Hwang JS, Lim ST, Yap SP, Tao M, Chong TW, Tan LH, Huynh H. An Epstein-Barr virus positive natural killer lymphoma xenograft derived for drug testing. Leukemia & Lymphoma. 49: 1161-7. PMID 18452087 DOI: 10.1080/10428190802043879 |
0.278 |
|
| 2011 |
Poon E, Ong SJ, Chuang XE, Lim WT, Mohd Zam NA, Chong TW, Al Jajeh I, Mancer K, Tan MH. 'Prechronous' metastasis in clear cell renal cell carcinoma: a case report. Journal of Medical Case Reports. 5: 181. PMID 21569512 DOI: 10.1186/1752-1947-5-181 |
0.217 |
|
| 2020 |
Wang B, Bellot GL, Iskandar K, Chong TW, Goh FY, Tai JJ, Schwarz H, Wong SC, Pervaiz S. Resveratrol attenuates TLR-4 mediated inflammation and elicits therapeutic potential in models of sepsis. Scientific Reports. 10: 18837. PMID 33139717 DOI: 10.1038/s41598-020-74578-9 |
0.199 |
|
| 2015 |
Chong TW, Goh FY, Sim MY, Huang HH, Thike DA, Lim WK, Teh BT, Tan PH. CD1d expression in renal cell carcinoma is associated with higher relapse rates, poorer cancer-specific and overall survival. Journal of Clinical Pathology. 68: 200-5. PMID 25477528 DOI: 10.1136/jclinpath-2014-202735 |
0.15 |
|
| 2010 |
Tan MH, Kanesvaran R, Li H, Tan HL, Tan PH, Wong CF, Chia KS, Teh BT, Yuen J, Chong TW. Comparison of the UCLA Integrated Staging System and the Leibovich Score in Survival Prediction for Patients With Nonmetastatic Clear Cell Renal Cell Carcinoma Urology. 75: 1365-1370.e3. PMID 20022084 DOI: 10.1016/j.urology.2009.07.1289 |
0.133 |
|
| 2015 |
Kumar P, Nandi S, Tan TZ, Ler SG, Chia KS, Lim WY, Bütow Z, Vordos D, De la Taille A, Al-Haddawi M, Raida M, Beyer B, Ricci E, Colombel M, Chong TW, et al. Highly sensitive and specific novel biomarkers for the diagnosis of transitional bladder carcinoma. Oncotarget. 6: 13539-49. PMID 25915536 DOI: 10.18632/ONCOTARGET.3841 |
0.121 |
|
| 2018 |
Lim WS, Chen K, Chong TW, Xiong GM, Birch WR, Pan J, Lee BH, Er PS, Salvekar AV, Venkatraman SS, Huang Y. A bilayer swellable drug-eluting ureteric stent: Localized drug delivery to treat urothelial diseases. Biomaterials. 165: 25-38. PMID 29501967 DOI: 10.1016/j.biomaterials.2018.02.035 |
0.12 |
|
| 2007 |
Lau LC, Tan PH, Chong TW, Foo KT, Yip S. Cytogenetic alterations in renal tumors: a study of 38 Southeast Asian patients. Cancer Genetics and Cytogenetics. 175: 1-7. PMID 17498551 DOI: 10.1016/j.cancergencyto.2007.01.002 |
0.116 |
|
| 2022 |
Lee LS, Sim AYL, Ong CW, Yang X, Ng CCY, Liu W, Rajasegaran V, Lim AMS, Aslim EJ, Ngo NT, Khor LY, Kanesvaran R, Allen JCJ, Tay KJ, Yuen JSP, ... Chong TW, et al. NEAR trial: A single-arm phase II trial of neoadjuvant apalutamide monotherapy and radical prostatectomy in intermediate- and high-risk prostate cancer. Prostate Cancer and Prostatic Diseases. PMID 35091711 DOI: 10.1038/s41391-022-00496-8 |
0.079 |
|
| 2013 |
Chen NK, Chong TW, Loh HL, Lim KH, Gan VH, Wang M, Kon OL. Negative regulatory responses to metabolically triggered inflammation impair renal epithelial immunity in diabetes mellitus. Journal of Molecular Medicine (Berlin, Germany). 91: 587-98. PMID 23149823 DOI: 10.1007/s00109-012-0969-x |
0.077 |
|
| 2011 |
Margulis V, Master VA, Cost NG, Leibovich BC, Joniau S, Kuczyk M, Mulders PF, Kirkali Z, Wirth MP, Hirao Y, Rawal S, Chong TW, Wood CG. International consultation on urologic diseases and the European Association of Urology international consultation on locally advanced renal cell carcinoma. European Urology. 60: 673-83. PMID 21752533 DOI: 10.1016/j.eururo.2011.06.042 |
0.071 |
|
| 2022 |
Yang X, Allen JC, Aslim EJ, Tay KJ, Yuen SPJ, Kanesvaran R, Chua MLK, Chong TW, Ho SSH, Lee LS. Patient-reported outcomes of a phase II neoadjuvant apalutamide (ARN-509) and radical prostatectomy in treatment of intermediate- to high-risk prostate cancer (NEAR) trial. International Journal of Urology : Official Journal of the Japanese Urological Association. PMID 36000794 DOI: 10.1111/iju.14994 |
0.07 |
|
| 2010 |
Huang H, Sim HG, Chong TW, Yuen JS, Cheng CW, Lau WK. Evaluation of data completeness of the prostate cancer registry after robotic radical prostatectomy. Annals of the Academy of Medicine, Singapore. 39: 848-53. PMID 21165525 |
0.064 |
|
| 2013 |
Poh PG, Tan BS, Tham SC, Tay KH, Htoo AM, Lin MB, Cheng CW, Chong TW, Foo KT, Lim WE. The use of n-butyl-2 cyanoacrylate as an embolic agent in the minimally invasive treatment of renal arteriovenous malformations. Annals of the Academy of Medicine, Singapore. 42: 207-9. PMID 23677217 |
0.06 |
|
| 2022 |
Lee LS, Sim AYL, Ong CW, Yang X, Ng CCY, Liu W, Rajasegaran V, Lim AMS, Aslim EJ, Ngo NT, Khor LY, Kanesvaran R, Allen JCJ, Tay KJ, Yuen JSP, ... Chong TW, et al. Correction to: NEAR trial: A single-arm phase II trial of neoadjuvant apalutamide monotherapy and radical prostatectomy in intermediate- and high-risk prostate cancer. Prostate Cancer and Prostatic Diseases. PMID 35288663 DOI: 10.1038/s41391-022-00522-9 |
0.06 |
|
| 2018 |
Huang H, Ng MY, Wu JT, Fong JCH, Begum S, Anita, Lam SSW, Yuen JSP, Chong TW, Ho HSS, Ng LG, Lee LS, Lau WKO. Automating the Renal Cell Carcinoma Registry in Singapore: A Case Study on the Integration of the Research Electronic Data Capture System with the Enterprise Data Warehouse. Journal of Registry Management. 45: 156-160. PMID 31490910 |
0.057 |
|
| 2013 |
Chan JY, Li H, Singh O, Mahajan A, Ramasamy S, Subramaniyan K, Kanesvaran R, Sim HG, Chong TW, Teo YY, Chia SE, Tan MH, Chowbay B. 8q24 and 17q prostate cancer susceptibility loci in a multiethnic Asian cohort. Urologic Oncology. 31: 1553-60. PMID 22561070 DOI: 10.1016/j.urolonc.2012.02.009 |
0.042 |
|
| 2022 |
Lu Y, Sundaram P, Li H, Chong TW. The effects of drinking bicarbonate-rich mineral water in calcium oxalate stone formers: an open label prospective randomized controlled study in an Asian cohort. International Urology and Nephrology. PMID 35781772 DOI: 10.1007/s11255-022-03256-8 |
0.012 |
|
| 2018 |
Chua JM, Rasheed S, Gogna A, Yuen JS, Lo RH, Ng LG, Chong TW, Irani FG, Too CW, Tan BS. Intermediate Outcomes of Image-Guided Radiofrequency Ablation of Renal Tumours. Annals of the Academy of Medicine, Singapore. 47: 119-122. PMID 29679090 |
0.01 |
|
| Hide low-probability matches. |